Diamond Therapeutics Inc. (“Diamond”), a clinical-stage drug development company and OnDosis, a developer of precision dosing technologies for oral solid medicines, announced today that they have entered into an agreement regarding the use of the OnDosis drug delivery platform, the Dosage Manager, in Diamond’s psychoactive low-dose psilocybin programs.

Diamond has been seeking a dosing technology partner capable of reliably delivering controlled doses of psilocybin, as part of its long-term development strategy. Following an evaluation process, the company selected OnDosis for its ability to support accurate and reproducible dosing and assist with compliance, as well as its potential to scale from clinical research into future commercial use. The OnDosis platform allows for precise dose titration and includes features intended to support controlled administration.

Diamond is currently conducting a Phase 2a clinical study evaluating low, sub-perceptual doses of its psilocybin formulation in patients with generalized anxiety disorder (GAD). The study is designed to better understand the relationship between dose, dosing frequency, safety, tolerability, and potential therapeutic benefit.

Under the agreement, Diamond is exploring the integration of its psilocybin formulation with the OnDosis device (Dosage Manager) for use in ongoing and future research and development activities. Subject to regulatory review and approval, the partnership aims to advance the integrated technology to a commercial setting, creating continuity between clinical development and later-stage deployment.

Diamond is investigating psychoactive low-dose psilocybin as a potential treatment approach for mood, psychiatric, and other disorders, with the aim of developing differentiated therapies that may help address unmet needs in mental health care.

CEO Statements

Judy Blumstock, CEO of Diamond Therapeutics, said: “Executing this agreement with OnDosis allows us to progress a prescription therapeutic drug delivery approach aligned with Diamond’s vision for accessible, well-tolerated psilocybin-based therapies. Precision dosing and integrated safety features are key enablers as we advance our psychoactive low dose programs targeting anxiety and other mental health conditions.”

Martin Olovsson, CEO of OnDosis said: “This important step highlights the applicability of our Dosage Manager in emerging therapeutic areas such as psychedelic medicine. By enabling individualized dosing whilst supporting controlled administration, we aim to support treatment models suitable for home use while reducing demands on healthcare systems.”

_

About Diamond Therapeutics

Diamond Therapeutics is a clinical-stage drug development company based in Toronto, Canada and Birmingham, Alabama. The company is dedicated to developing new and better therapies for mental health conditions by unlocking the fundamental mechanisms underlying these disorders. Diamond’s focus is on safe, effective treatments suitable for broad patient populations. Learn more at: www.diamondthera.com

About OnDosis

OnDosis is a Swedish life science company advancing the delivery of oral solid medicines through an intelligent, connected drug delivery platform enabling precise, individualized dosing to improve patient outcomes and healthcare efficiency.

For more information, please contact:

Judy Blumstock CEO, Diamond Therapeutics judy@diamondthera.com

Martin Olovsson CEO, OnDosisOnDosis m.olovsson@OnDosis.com

_

Cautionary Statement Regarding Forward-Looking Information

This press release contains forward-looking statements, including statements regarding the potential use of the OnDosis platform in future clinical and commercial settings, the development of Diamond’s low-dose psilocybin programs, and the potential therapeutic applications of low-dose psilocybin. Forward-looking statements are based on current expectations and assumptions including integration with the OnDosis technology and are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, regulatory developments, clinical trial outcomes, and the ability to successfully integrate and deploy new technologies. Diamond undertakes no obligation to update these statements except as required by law. All Diamond Therapeutics product candidates are investigational and have not been approved by regulatory authorities. Any future development, clinical use, or commercialization will depend on the results of ongoing and future studies and on applicable regulatory review and approval.